Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s stock price rose 5.5% during mid-day trading on Monday . The stock traded as high as $6.50 and last traded at $6.36. Approximately 5,209,043 shares were traded during trading, a decline of 23% from the average daily volume of 6,721,588 shares. The stock had previously closed at $6.03.
Wall Street Analyst Weigh In
RXRX has been the topic of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group reduced their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $9.25.
View Our Latest Analysis on Recursion Pharmaceuticals
Recursion Pharmaceuticals Stock Up 9.8 %
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business’s quarterly revenue was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.43) EPS. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Insider Activity at Recursion Pharmaceuticals
In related news, CEO Christopher Gibson sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total value of $123,200.00. Following the transaction, the chief executive officer now owns 762,656 shares of the company’s stock, valued at $4,697,960.96. This trade represents a 2.56 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $7.00, for a total transaction of $42,000.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,647,966. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 107,788 shares of company stock worth $724,691. Insiders own 15.75% of the company’s stock.
Institutional Trading of Recursion Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of RXRX. Allspring Global Investments Holdings LLC bought a new position in Recursion Pharmaceuticals in the third quarter worth approximately $25,000. Farther Finance Advisors LLC grew its position in shares of Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares in the last quarter. KBC Group NV raised its holdings in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares in the last quarter. Amalgamated Bank lifted its stake in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares during the period. Finally, San Luis Wealth Advisors LLC purchased a new stake in Recursion Pharmaceuticals in the third quarter worth about $69,000. Institutional investors own 89.06% of the company’s stock.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
- Five stocks we like better than Recursion Pharmaceuticals
- Learn Technical Analysis Skills to Master the Stock Market
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- Why Are These Companies Considered Blue Chips?
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- Ride Out The Recession With These Dividend KingsĀ
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.